PDF(1026 KB)
Effect of general transcription factor 2I on temozolomide chemotherapy resistance of glioblastoma
Jianguo ZHOU,Hongjian JIANG,Qihui ZHU,Gengqiang ZHANG,Qilin DENG,Ling QI,Kaishu LI,Hongquan YU
PDF(1026 KB)
PDF(1026 KB)
Effect of general transcription factor 2I on temozolomide chemotherapy resistance of glioblastoma
),Hongquan YU1()Objective To discuss the effect of general transcription factor 2I （GTF2I） on the chemotherapeutic resistance to temozolomide in the glioblastoma multiforme （GBM）， and to clarify its mechanism. Methods Bioinformatics analysis was used to identify the common transcription factors for DNA methyltransferase 1 （DNMT1）， damage-specific DNA binding protein 1 （DDB1）， chromobox protein homolog 5 （CBX5）， and xeroderma pigmentosum complementation group C （XPC） in GBM tissue using the transcription factor prediction website （PROMO website）； correlation analysis and survival analysis for DDB1， CBX5， XPC， and DNMT1 with GTF2I and methylguanine methyltransferase （MGMT） were conducted based on The Cancer Genome Atlas （TCGA） Database；small interfering RNAs （siRNAs） were used to transfect and silence the gene expression of MGMT and GTF2I in the human T98 GBM cells and LN229 glioma cells； real-time fluorescence quantitative PCR （RT-qPCR） method was used to detect the expression level of the gene mRNA. After silencing the GTF2I gene， plate clone formation assay was used to detect the colon forming ability of the tumor cells， and CCK-8 assay was used to detect the sensitivity of the cells to temozolomide. Results The bioinformatics analysis results showed that the expression levels of DDB1， CBX5， XPC， and DNMT1 were significantly positively correlated with the expression level of GTF2I in GBM tissue （P<0.05）， and were negatively correlated with the expression level of MGMT （P<0.05）. The expression level of GTF2I was significantly negatively correlated with the expression level of MGMT （P<0.05）. Excluding the GBM patients who did not receive temozolomide treatment， the survival analysis results indicated that the patients with high expression of GTF2I had a decreased overall survival time. After silencing the MGMT gene， the expression levels of GTF2I， DDB1， CBX5， and XPC mRNA in the human brain glioma T98 cells were increased （P<0.001）； after silencing the GTF2I gene， the expression level of MGMT mRNA in the human brain glioma LN229 cells was increased （P<0.05）， while the expression levels of DDB1， CBX5， XPC， and DNMT1 mRNA were significantly decreased （P<0.05 or P<0.001）. The plate clone formation assay results showed that there was no significant difference in the clone formation ability of the cells before and after silencing the GTF2I gene （P=0.138）. The CCK-8 assay results showed that compared with control group，the viability of the cells in observation group was decreased （P<0.05）. Conclusion The transcription factor GTF2I regulates the expressions of key DNA damage repair protein mRNA， including MGMT， DDB1， CBX5， and XPC， and is involved in the chemotherapeutic resistance of the GBM cells to temozolomide；GTF2I may represent a potential new therapeutic target for the GBM.
Glioblastoma multiforme / Temozolomide resistance / Universal transcription factor 2I / Methylguanine methyltransferase / Key DNA damage repair genes
R739.41
| 1 | LOUIS D N， PERRY A， WESSELING P， et al. The 2021 WHO classification of tumors of the central nervous system： a summary［J］. Neuro-oncology， 2021， 23（8）： 1231-1251. |
| 2 | DE SILVA M I， STRINGER B W， BARDY C. Neuronal and tumourigenic boundaries of glioblastoma plasticity［J］. Trends Cancer， 2023， 9（3）： 223-236. |
| 3 | HORBINSKI C， BERGER T， PACKER R J， et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours［J］. Nat Rev Neurol， 2022， 18（9）： 515-529. |
| 4 | ZHANG X N， YANG K D， CHEN C， et al. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling［J］. Cell Res， 2021， 31（10）： 1072-1087. |
| 5 | TOMAR M S， KUMAR A， SRIVASTAVA C， et al. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance［J］.Biochim Biophys Acta Rev Cancer， 2021， 1876（2）： 188616. |
| 6 | CHEN X Y， ZHANG M J， GAN H Y， et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma［J］. Nat Commun， 2018， 9（1）： 2949. |
| 7 | CHRISTMANN M， KAINA B. Epigenetic regulation of DNA repair genes and implications for tumor therapy［J］.Mutat Res Rev Mutat Res，2019，780： 15-28. |
| 8 | WU S F， LI X L， GAO F， et al. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma［J］. Neuro Oncol， 2021，23（6）： 920-931. |
| 9 | OMURO A， BRANDES A A， CARPENTIER A F， et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter： an international randomized phase Ⅲ trial［J］.Neuro Oncol，2023，25（1）： 123-134. |
| 10 | YI G Z， HUANG G L， GUO M L， et al. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2［J］. Brain， 2019， 142（8）： 2352-2366. |
| 11 | XIE J L， LIU J， LIAN Z Y， et al. Association of GTF2IRD1-GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients［J］. Neural Regen Res， 2019， 14（2）： 346-353. |
| 12 | KOPP N D， NYGAARD K R， LIU Y T， et al. Functions of Gtf2i and Gtf2ird1 in the developing brain： transcription， DNA binding and long-term behavioral consequences［J］. Hum Mol Genet， 2020， 29（9）： 1498-1519. |
| 13 | DEURLOO M H S， TURLOVA E， CHEN W L，et al. Transcription factor 2I regulates neuronal development via TRPC3 in 7q11.23 disorder models［J］. Mol Neurobiol， 2019， 56（5）： 3313-3325. |
| 14 | FAN A X， PAPADOPOULOS G L， HOSSAIN M A， et al. Genomic and proteomic analysis of transcription factor TFⅡ - Ⅰ reveals insight into the response to cellular stress［J］. Nucleic Acids Res， 2014， 42（12）：7625-7641. |
| 15 | ROY A L. Role of the multifunctional transcription factor TFⅡ - Ⅰ in DNA damage repair［J］. DNA Repair， 2021， 106： 103175. |
| 16 | MESSEGUER X， ESCUDERO R， FARRé D， et al. PROMO： detection of known transcription regulatory elements using species-tailored searches［J］. Bioinformatics， 2002， 18（2）： 333-334. |
| 17 | FARRé D， ROSET R， HUERTA M， et al. Identification of patterns in biological sequences at the ALGGEN server： PROMO and MALGEN［J］. Nucleic Acids Res， 2003， 31（13）： 3651-3653. |
| 18 | LI K S， HUANG G L， WANG Z Y， et al. IKBIP， a novel glioblastoma biomarker， maintains abnormal proliferation of tumor cells by inhibiting the ubiquitination and degradation of CDK4［J］. Biochim Biophys Acta Mol Basis Dis， 2023， 1869（1）： 166571. |
| 19 | LIU D Z， CHENG Y， QIAO S， et al. Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma［J］.ACS Nano，2022，16（5）：7409-7427. |
| 20 | HAJHEIDARI M， HUANG S S C. Elucidating the biology of transcription factor-DNA interaction for accurate identification of cis-regulatory elements［J］. Curr Opin Plant Biol， 2022， 68： 102232. |
| 21 | VIEIRA M S， SANTOS A K， VASCONCELLOS R， et al. Neural stem cell differentiation into mature neurons： mechanisms of regulation and biotechnological applications［J］. Biotechnol Adv， 2018， 36（7）： 1946-1970. |
| 22 | TANIKAWA M， WADA-HIRAIKE O， YOSHIZAWA-SUGATA N，et al.Role of multifunctional transcription factor TFⅡ - Ⅰ and putative tumour suppressor DBC1 in cell cycle and DNA double strand damage repair［J］. Br J Cancer， 2013， 109（12）： 3042-3048. |
| 23 | WONG K K. DNMT1： a key drug target in triple-negative breast cancer［J］. Semin Cancer Biol， 2021， 72： 198-213. |
/
| 〈 |
|
〉 |
AI Summary
